Stock Research for ACRX

ACRX

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

ACRX Stock Chart & Research Data

The ACRX chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ACRX chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


ACRX Due diligence Resources & Stock Charts

The ACRX stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ACRX Detailed Price Forecast - CNN Money CNN View ACRX Detailed Summary - Google Finance
Yahoo View ACRX Detailed Summary - Yahoo! Finance Zacks View ACRX Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View ACRX Trends & Analysis - Trade-Ideas Barrons View ACRX Major Holders - Barrons
NASDAQ View ACRX Call Transcripts - NASDAQ Seeking View ACRX Breaking News & Analysis - Seeking Alpha
Spotlight View ACRX Annual Report - CompanySpotlight.com OTC Report View ACRX OTC Short Report - OTCShortReport.com
TradeKing View ACRX Fundamentals - TradeKing Charts View ACRX SEC Filings - Bar Chart
WSJ View Historical Prices for ACRX - The WSJ Morningstar View Performance/Total Return for ACRX - Morningstar
MarketWatch View the Analyst Estimates for ACRX - MarketWatch CNBC View the Earnings History for ACRX - CNBC
StockMarketWatch View the ACRX Earnings - StockMarketWatch MacroAxis View ACRX Buy or Sell Recommendations - MacroAxis
Bullish View the ACRX Bullish Patterns - American Bulls Short Pains View ACRX Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View ACRX Stock Mentions - StockTwits PennyStocks View ACRX Stock Mentions - PennyStockTweets
Twitter View ACRX Stock Mentions - Twitter Invest Hub View ACRX Investment Forum News - Investor Hub
Yahoo View ACRX Stock Mentions - Yahoo! Message Board Seeking Alpha View ACRX Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for ACRX - SECform4.com Insider Cow View Insider Transactions for ACRX - Insider Cow
CNBC View ACRX Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ACRX - OTC Markets
Yahoo View Insider Transactions for ACRX - Yahoo! Finance NASDAQ View Institutional Holdings for ACRX - NASDAQ


Stock Charts

FinViz View ACRX Stock Insight & Charts - FinViz.com StockCharts View ACRX Investment Charts - StockCharts.com
BarChart View ACRX Stock Overview & Charts - BarChart Trading View View ACRX User Generated Charts - Trading View




Latest Financial News for ACRX


As powerful new opioid nears FDA approval, critics ask if U.S. is stoking its drug crisis
Posted on Tuesday October 23, 2018

As a new medication intended for quick pain relief nears a U.S. approval decision, critics worry about putting another strong opioid on the market amid a devastating opioid crisis.


AcelRx Provides Updated Comments Following Positive FDA Advisory Committee Meeting
Posted on Friday October 19, 2018

REDWOOD CITY, Calif. , Oct. 19, 2018 /PRNewswire/ -- In response to opinions expressed following the U.S. Food and Drug Administration (FDA) Anesthetic and Analgesic Drug Products Advisory Committee meeting ...


Controversy builds over potent new opioid medication as U.S. senator calls on FDA to reject the drug
Posted on Friday October 19, 2018

A new, potent opioid medication intended for immediate pain relief has become the center of a maelstrom of controversy as it nears a Food and Drug Administration approval decision early next month. The latest salvo came from Sen. Edward Markey (D-Mass.) on Thursday, calling on the FDA to reject the medication as it is "a thousand times more likely to be abused, and a thousand times more likely to kill." The medication, Dsuvia, is made by the Redwood City, Calif.-based drugmaker AcelRx Pharmaceuticals Inc. , and consists of tablets delivered in an applicator and absorbed beneath the tongue; the company says that the product is intended for moderate-to-severe pain in adults under medical supervision. Dsuvia could help give patients faster and less invasive pain relief than existing options like intramuscular opioid injections, AcelRx says. But critics, including Markey and Public Citizen health researcher Dr. Meena Aladdin, say that the product, which uses an even stronger opioid than the already-potent opioid fentanyl, could pose serious harm and does not offer any real medical benefits over existing options. A FDA advisory committee recommended that the FDA approve Dsuvia last week, in a 10-3 vote. The FDA often follows advisory committee recommendations but is not obligated to do so; a decision is expected by November 3. However, the FDA advisory committee's chair, Dr. Raeford Brown, was not at the committee vote, Markey noted, and Brown has publicly expressed concerns about the product. AcelRx shares declined 1% in Friday morning trade. Shares have surged 39.6% to $4.12 over the last three months, compared with a 0.5% decline in the S&P 500 and a nearly 2% rise in the Dow Jones Industrial Average .


Report: Exploring Fundamental Drivers Behind CURO Group, BiondVax Pharmaceuticals, AMAG Pharmaceuticals, AcelRx Pharmaceuticals, Ballard Power, and Rhythm Pharmaceuticals — New Horizons, Emerging Trends, and Upcoming Developments
Posted on Wednesday October 17, 2018

NEW YORK, Oct. 17, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.